急性照护医院内医院获得性耐甲氧西林金黄色葡萄球菌感染的预防
主要终点实验室确认MRSA医院获得性菌血症事件较基线12个月下降2.3事件/万患者日(95%CI -2.8~-1.9;P<.001),相对下降65%(95%CI -73%~-58%;P<.001)。次要终点医院获得性MRSA临床培养、全因医院获得性菌血症和中心静脉导管相关血流感染亦显著下降。
要点
- 医院第4天及以后MRSA临床培养下降5.6事件/万患者日(95%CI -7.8~-3.3;P<.001),相对下降39%。
- 全因医院获得性菌血症下降10.5事件/万患者日(95%CI -13.8~-7.1;P<.001),相对下降37%。
- 中心静脉导管相关血流感染下降3.5事件/万中心静脉导管日(95%CI -5.5~-1.5;P<.001),相对下降31%。
- 项目核心干预包括氯己定沐浴、鼻腔MRSA去定植、环境消毒及阻断人际传播和器械相关感染,教育对象覆盖护士、感染预防人员、医师、护理助理和环境服务人员。
适用人群与场景
- 参与医院包括31所(33%)学术医学中心、42所(45%)非学术医学中心教学医院、21所(22%)非教学社区或其他医院。
诊断标准与关键阈值
- 主要终点为实验室确认的MRSA医院获得性菌血症事件率(每万患者日)。
- 次要终点包括医院第4天及以后MRSA临床培养、全因医院获得性菌血症和中心静脉导管相关血流感染。
处置流程与药物剂量
- 第一步:参加项目提供的22场网络研讨会和持续教育内容。
- 第二步:在单元内实施循证MRSA感染预防干预,主要焦点为氯己定沐浴、鼻腔MRSA去定植、环境消毒、阻断人际MRSA传播和器械相关感染干预。
- 教育对象包括护士、感染预防人员、医师、护理助理和环境服务人员。
- 原文未提及具体药物剂量、给药途径、频次或疗程。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 主要终点:实验室确认MRSA医院获得性菌血症下降2.3事件/万患者日(95%CI -2.8~-1.9;P<.001),相对下降65%(95%CI -73%~-58%;P<.001)。
- 次要终点:医院第4天及以后MRSA临床培养下降5.6事件/万患者日(95%CI -7.8~-3.3;P<.001),相对下降39%(95%CI -50%~-29%;P<.001)。
- 次要终点:全因医院获得性菌血症下降10.5事件/万患者日(95%CI -13.8~-7.1;P<.001),相对下降37%(95%CI -45%~-30%;P<.001)。
- 次要终点:中心静脉导管相关血流感染下降3.5事件/万中心静脉导管日(95%CI -5.5~-1.5;P<.001),相对下降31%(95%CI -45%~-17%;P<.001)。
证据类型、等级与局限
- 证据类型:质量改进研究(前后比较设计),非随机对照试验。
- 局限:单元自愿参加,无平行对照组,不能排除时间趋势或同期其他干预的影响;原文未报告证据等级或推荐强度。
对床旁实践的改变
- 在ICU和非ICU单元实施以氯己定沐浴、鼻腔MRSA去定植、环境消毒及阻断人际传播和器械相关感染为核心的多组分预防 bundle,与MRSA医院获得性菌血症及其他医院获得性感染下降相关。
- 项目教育内容覆盖护士、感染预防人员、医师、护理助理和环境服务人员,提示多角色参与是实施的一部分。
- 由于为前后比较设计,结果不能证明因果关系;适用人群为自愿参加的ICU和非ICU单元,不适用于推断患者层面的个体化干预效果。
指南或共识出处
- 原文未提及具体指南或共识名称;项目为Agency for Healthcare Research and Quality(AHRQ)Safety Program for MRSA Prevention。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Methicillin-resistant Staphylococcus aureus (MRSA) infections are major contributors to morbidity and mortality among hospitalized patients. Despite evidence-based guidelines, opportunities remain to improve the implementation of MRSA infection prevention.
OBJECTIVE: To determine whether an educational quality improvement program is associated with improved evidence-based practices and prevention of MRSA infections among hospitalized patients.
DESIGN, SETTING, AND PARTICIPANTS: This quality improvement study evaluates the Agency for Healthcare Research and Quality's Safety Program for MRSA Prevention, which was conducted and evaluated in volunteer intensive care units (ICUs) and non-ICUs in US acute care hospitals from April 2022 through September 2023. Data analysis, which was conducted between October 2024 and January 2025, compared data from the project period to the previous 12 months of baseline data.
EXPOSURES: The program provided 22 webinars and durable educational content and assisted units with implementing evidence-based MRSA infection prevention interventions. Webinars targeted nurses, infection preventionists, physicians, nursing assistants, and environmental services personnel. The major foci were chlorhexidine bathing, nasal MRSA decolonization, environmental disinfection, and interventions to prevent person-based MRSA transmission and device-related infections.
MAIN OUTCOMES AND MEASURES: The primary outcome was the rate of laboratory-identified, MRSA hospital-onset bacteremia (HOB) events. Secondary outcomes included hospital-onset clinical cultures growing MRSA, all-cause HOB, and central line-associated bloodstream infections. The χ2 test was used to compare binary outcomes.
RESULTS: One hundred ninety-three hospital units completed the program (106 ICUs and 87 non-ICUs from 94 hospitals), including units from 31 (33%) academic medical centers, 42 (45%) non-academic medical centers teaching hospitals, and 21 (22%) nonteaching community or other hospitals. Between baseline and the end of the program, laboratory-identified MRSA HOB events decreased by -2.3 events per 10 000 patient-days (95% CI, -2.8 to -1.9 events per 10 000 patient-days; P < .001), or -65% (95% CI, -73% to -58%; P < .001). Clinical cultures growing MRSA from hospital day 4 or later decreased by -5.6 events per 10 000 patient-days (95% CI, -7.8 to -3.3 events per 10 000 patient-days; P < .001), or -39% (95% CI, -50% to -29%; P < .001). All-cause HOB decreased by -10.5 events per 10 000 patient-days (95% CI, -13.8 to -7.1 events per 10 000 patient-days; P < .001), or -37% (95% CI, -45% to -30%; P < .001). Central line-associated bloodstream infections decreased by -3.5 events per 10 000 central-line days (95% CI, -5.5 to -1.5 events per 10 000 central-line days; P < .001), or -31% (95% CI, -45% to -17%; P < .001).
CONCLUSIONS AND RELEVANCE: In this quality improvement study of MRSA prevention in ICU and non-ICU hospital settings, the program was associated with significantly reduced rates of laboratory-identified MRSA HOB events and other infections among participating hospital units. The program content is publicly available and may help ICUs and non-ICUs reduce MRSA infection among hospitalized patients.
参考来源
- Maragakis LL, Miller MA, Gao Y, et al. Hospital-Onset Methicillin-Resistant Staphylococcus aureus Prevention in Acute Care Hospitals. JAMA Netw Open. 2026. PMID: 42658494. doi:10.1001/jamanetworkopen.2026.31225
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。